Reported 28 days ago
Pfizer (PFE) exceeded third quarter earnings expectations and has raised its full-year guidance, reporting a 31% increase in revenue mainly supported by sales of its antiviral pill, Paxlovid. Despite a strong performance driven by COVID-19, analysts highlight that the critical issue for Pfizer moving forward is the sustainability of its COVID-related revenue and how this will stabilize in the long term amidst ongoing uncertainties.
Source: YAHOO